Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08), Zacks reports.
Checkpoint Therapeutics Stock Up 4.4 %
Shares of NASDAQ:CKPT opened at $3.78 on Friday. Checkpoint Therapeutics has a fifty-two week low of $1.36 and a fifty-two week high of $3.97. The firm has a 50-day simple moving average of $2.79 and a 200 day simple moving average of $2.33.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Checkpoint Therapeutics in a report on Thursday.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
See Also
- Five stocks we like better than Checkpoint Therapeutics
- Basic Materials Stocks Investing
- Top-Performing Non-Leveraged ETFs This Year
- Pros And Cons Of Monthly Dividend Stocks
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- How to Use Stock Screeners to Find Stocks
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
